Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

H5N1 strain-specific hemagglutinin CD4+ T cell epitopes restricted by HLA DR4.

Yang J, Gebe JA, Huston L, James E, Tan V, Yue BB, Nepom GT, Kwok WW.

Vaccine. 2009 Jun 12;27(29):3862-9. doi: 10.1016/j.vaccine.2009.04.019. Epub 2009 May 3.

2.

Identifying conserved DR1501-restricted CD4(+) T-cell epitopes in avian H5N1 hemagglutinin proteins.

Wang SF, Yao L, Liu SJ, Chong P, Liu WT, Chen YM, Huang JC.

Viral Immunol. 2010 Dec;23(6):585-93. doi: 10.1089/vim.2010.0058.

PMID:
21142444
3.

Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.

Zinckgraf JW, Sposato M, Zielinski V, Powell D, Treanor JJ, von Hofe E.

Vaccine. 2009 Aug 27;27(39):5393-401. doi: 10.1016/j.vaccine.2009.06.081. Epub 2009 Jul 9.

PMID:
19596415
4.

A T cell epitope-based vaccine protects against chlamydial infection in HLA-DR4 transgenic mice.

Li W, Murthy AK, Lanka GK, Chetty SL, Yu JJ, Chambers JP, Zhong G, Forsthuber TG, Guentzel MN, Arulanandam BP.

Vaccine. 2013 Nov 19;31(48):5722-8. doi: 10.1016/j.vaccine.2013.09.036. Epub 2013 Oct 1.

5.

Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 derived from the H5N1 subtype of influenza A viruses.

Sun Y, Liu J, Yang M, Gao F, Zhou J, Kitamura Y, Gao B, Tien P, Shu Y, Iwamoto A, Chen Z, Gao GF.

J Gen Virol. 2010 Apr;91(Pt 4):919-30. doi: 10.1099/vir.0.016766-0. Epub 2009 Dec 2.

6.

Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus.

Roti M, Yang J, Berger D, Huston L, James EA, Kwok WW.

J Immunol. 2008 Feb 1;180(3):1758-68.

7.

A human CD4+ T cell epitope in the influenza hemagglutinin is cross-reactive to influenza A virus subtypes and to influenza B virus.

Babon JA, Cruz J, Ennis FA, Yin L, Terajima M.

J Virol. 2012 Sep;86(17):9233-43. doi: 10.1128/JVI.06325-11. Epub 2012 Jun 20. Erratum in: J Virol. 2013 Aug;87(16):9396.

8.

Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model.

Ichihashi T, Yoshida R, Sugimoto C, Takada A, Kajino K.

PLoS One. 2011;6(9):e24626. doi: 10.1371/journal.pone.0024626. Epub 2011 Sep 19.

9.

T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis-associated and nonassociated HLA-DR4 alleles.

Cope AP, Patel SD, Hall F, Congia M, Hubers HA, Verheijden GF, Boots AM, Menon R, Trucco M, Rijnders AW, Sønderstrup G.

Arthritis Rheum. 1999 Jul;42(7):1497-507.

10.

A reductionist cell-free major histocompatibility complex class II antigen processing system identifies immunodominant epitopes.

Hartman IZ, Kim A, Cotter RJ, Walter K, Dalai SK, Boronina T, Griffith W, Lanar DE, Schwenk R, Krzych U, Cole RN, Sadegh-Nasseri S.

Nat Med. 2010 Nov;16(11):1333-40. doi: 10.1038/nm.2248. Epub 2010 Oct 31.

11.

Searching immunodominant epitopes prior to epidemic: HLA class II-restricted SARS-CoV spike protein epitopes in unexposed individuals.

Yang J, James E, Roti M, Huston L, Gebe JA, Kwok WW.

Int Immunol. 2009 Jan;21(1):63-71. doi: 10.1093/intimm/dxn124. Epub 2008 Dec 2.

13.

Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263-275) epitope: an MHC anchor variant peptide for immune modulation.

Boots AM, Hubers H, Kouwijzer M, den Hoed-van Zandbrink L, Westrek-Esselink BM, van Doorn C, Stenger R, Bos ES, van Lierop MJ, Verheijden GF, Timmers CM, van Staveren CJ.

Arthritis Res Ther. 2007;9(4):R71.

14.

Identification of a MHC class-II restricted epitope in carcinoembryonic antigen.

Shen L, Schroers R, Hammer J, Huang XF, Chen SY.

Cancer Immunol Immunother. 2004 May;53(5):391-403. Epub 2003 Nov 18.

PMID:
14624313
15.

CD4+ T cells recognize unique and conserved 2009 H1N1 influenza hemagglutinin epitopes after natural infection and vaccination.

Yang J, James E, Gates TJ, DeLong JH, LaFond RE, Malhotra U, Kwok WW.

Int Immunol. 2013 Aug;25(8):447-57. doi: 10.1093/intimm/dxt005. Epub 2013 Mar 22.

16.

Immunization with cross-conserved H1N1 influenza CD4+ T-cell epitopes lowers viral burden in HLA DR3 transgenic mice.

Moise L, Tassone R, Latimer H, Terry F, Levitz L, Haran JP, Ross TM, Boyle CM, Martin WD, De Groot AS.

Hum Vaccin Immunother. 2013 Oct;9(10):2060-8. doi: 10.4161/hv.26511. Epub 2013 Sep 17.

17.

T cell epitopes of human myelin oligodendrocyte glycoprotein identified in HLA-DR4 (DRB1*0401) transgenic mice are encephalitogenic and are presented by human B cells.

Forsthuber TG, Shive CL, Wienhold W, de Graaf K, Spack EG, Sublett R, Melms A, Kort J, Racke MK, Weissert R.

J Immunol. 2001 Dec 15;167(12):7119-25.

18.

Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.

Tao P, Luo M, Pan R, Ling D, Zhou S, Tien P, Pan Z.

Antiviral Res. 2009 Mar;81(3):253-60. doi: 10.1016/j.antiviral.2008.12.009. Epub 2009 Jan 9.

PMID:
19135483
19.

A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses.

Hu H, Voss J, Zhang G, Buchy P, Zuo T, Wang L, Wang F, Zhou F, Wang G, Tsai C, Calder L, Gamblin SJ, Zhang L, Deubel V, Zhou B, Skehel JJ, Zhou P.

J Virol. 2012 Mar;86(6):2978-89. doi: 10.1128/JVI.06665-11. Epub 2012 Jan 11.

20.

Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.

Osen W, Soltek S, Song M, Leuchs B, Steitz J, Tüting T, Eichmüller SB, Nguyen XD, Schadendorf D, Paschen A.

PLoS One. 2010 Nov 30;5(11):e14137. doi: 10.1371/journal.pone.0014137.

Supplemental Content

Support Center